Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,950 | $40,109 | $43,653 | $43,075 |
| % Growth | 4.6% | -8.1% | 1.3% | – |
| Cost of Goods Sold | $20,625 | $20,072 | $21,330 | $19,861 |
| Gross Profit | $21,325 | $20,037 | $22,323 | $23,214 |
| % Margin | 50.8% | 50% | 51.1% | 53.9% |
| R&D Expenses | $2,823 | $2,719 | $2,852 | $2,738 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,651 | $10,883 | $11,109 | $11,276 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,474 | $13,602 | $13,961 | $14,014 |
| Operating Income | $6,825 | $6,435 | $8,362 | $9,200 |
| % Margin | 16.3% | 16% | 19.2% | 21.4% |
| Other Income/Exp. Net | $188 | $229 | -$56 | -$989 |
| Pre-Tax Income | $7,013 | $6,664 | $8,306 | $8,211 |
| Tax Expense | -$6,389 | $941 | $1,373 | $1,140 |
| Net Income | $13,402 | $5,723 | $6,933 | $7,071 |
| % Margin | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS | 7.67 | 3.3 | 3.94 | 3.97 |
| % Growth | 132.4% | -16.2% | -0.8% | – |
| EPS Diluted | 7.64 | 3.27 | 3.91 | 3.94 |
| Weighted Avg Shares Out | 1,732 | 1,734 | 1,753 | 1,775 |
| Weighted Avg Shares Out Dil | 1,748 | 1,749 | 1,764 | 1,789 |
| Supplemental Information | – | – | – | – |
| Interest Income | $344 | $385 | $183 | $43 |
| Interest Expense | $603 | $698 | $315 | $410 |
| Depreciation & Amortization | $3,218 | $3,243 | $3,267 | $3,538 |
| EBITDA | $10,834 | $10,605 | $11,888 | $12,159 |
| % Margin | 25.8% | 26.4% | 27.2% | 28.2% |